A novel formulation may prevent blood vessel growth and vascular leakage in the retina
There is more than one way to target vascular endothelial growth factor (VEGF) in wet age-related macular degeneration (AMD) because of the recognition of the number of signaling pathways in the retina.
To now, most of the research has focused on targeting VEGF-A. In a press release, Opthea Limited Inc. announced its formulation of sozinibercept (OPT-302), a novel, first-in-class formulation to target the VEGF-C and -D pathways. The current published review1 shows sozinibercept’s potential to prevent blood vessel growth and vascular leakage in the retina as a treatment for wet AMD. The recognition is that the “pathophysiology is broader than dysregulation or overproduction of VEGF-A,” the investigators pointed out.
In addition, the review discusses both the role of VEGF-C and VEGF-D signaling in both health and disease and strategies to target the VEGF-C and -D signaling pathways to focus on better visual outcomes for this patient population.
The expectation is that the company will report topline data for the COAST trial (NCT04757636) in early Q2 and for the ShORe trial (NCT04757610) in mid CY 2025.
In the prospective, randomised, controlled Phase 2b trial,2 366 treatment-naïve patients with wet AMD received sozinibercept in combination with standard-of-care ranibizumab (Lucentis, Genentech Inc.). Sozinibercept combination therapy met the pre-specified primary efficacy endpoint of a statistically superior gains in visual acuity at 24 weeks compared to ranibizumab alone. The secondary outcomes were positive with the combination therapy, including more patients gaining vision of 10 or more letters, improved anatomy, with reduced swelling and vascular leakage and a favorable safety profile, the company reported.
According to Frederic Guerard, PharmD, Chief Executive Officer of Opthea, “This review underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina and deliver superior visual outcomes in wet AMD patients when combined with standard-of-care anti-VEGF-A therapies. Our fully enrolled sozinibercept Phase 3 clinical program in wet AMD is designed to assess the safety and superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A therapies compared to standard-of-care alone.”
Sozinibercept has received Fast Track Designation from the US FDA for the treatment of wet AMD, according to the press release.
References
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.